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Summary
Managing osteoarthritis (OA) with structure-modifying agents (SMAs) is an important emerging topic receiving increased attention from both
lay individuals and health care professionals as a promising alternative in the management of OA.
Objective: To review the methodology and outcome parameters purported to be used in the assessment of the structure-modifying potential
of various interventions.
Design: A Medline search was performed to select the relevant published articles. This review does not go into detail about various aspects
of the design and conduct of structure-modifying studies; however, a vast number of relevant references are provided and may be accessed
by interested readers.
Results: Enhancing the feasibility of SMAs trials aimed at documenting efficacy can be accomplished by carefully selecting: (1) the outcome
parameters, (2) the imaging methodology, and (3) the patient population. Most of the relevant issues that need to be considered by
investigators before embarking on a study of this nature have been addressed in this article.
Conclusion: Most of the evidence to date focuses on the superiority of the radiographic-based techniques in measuring joint space narrowing
among a homogeneous population of OA patients. More research is warranted before other techniques such as ultrasound, chondroscopy,
and magnetic resonance imaging, can be proven to be reliable. © 2001 OsteoArthritis Research Society International
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Osteoarthritis (OA) is the most prevalent chronic joint
disorder in the U.S.A. and in the world1,2. Lawrence et al.2
estimated that nearly 21 million Americans had clinical
symptoms and signs of OA in 1990. The fact that OA is
symptomatic in only half of the patients with radiographic
OA3 emphasizes the magnitude of the problem. The
burden of OA disability and dependence among older
Americans is second only to chronic heart disease as
the primary diagnosis leading to adults receiving Social
Security Disability payments2. The extent to which OA
afflicts Americans is reflected in the cost for diagnosis and
treatment4. Summarizing data from several studies, Yelin5
estimated the cost of OA in the US at $15.5 billion (in 1994
dollars). In addition, the disability and medical care costs
associated with OA will continue to escalate as the average
life expectancy increases to 83.1 years for women and
75 years for men by the year 20406.
The knee joint is a frequently involved joint in OA7 with
great social cost and disability1,7,8. This article will highlight
various aspects related to the structure modification488research on knee joint OA, since the majority of the
literature on radiographic progression of OA is based on
studies of OA of the knee with follow up periods that ranged
from 3 to 12 years9–22. To enhance the feasibility of
structure-modifying agents (SMAs) trials aimed at docu-
menting efficacy, two important issues must be addressed.
The first is reducing the variability of the outcome measure-
ment and the second is shortening the required length of
such a trial. Researchers can accomplish these objectives
by carefully selecting: (1) the outcome parameters, (2) the
imaging methodology, and (3) the patient population.Outcome parameters and imaging methodology
The need of a reliable method for the evaluation of
putative structure-modifying agents has led to a variety of
different clinical, imaging and laboratory investigations.
These will be discussed separately in the following section.Received 9 June 2000; revision requested 26 September 2000;
revision received 8 December 2000; accepted 17 January 2001.
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OA has both clinical and radiographic criteria. The
American College of Rheumatologists’ classification criteria
for OA23,24 has introduced some measure of standardiz-
ation, but they are not diagnostic criteria25. Based on these
criteria, for clinical study purposes, OA has two main
clinical outcomes, pain and functional disability. Tools to
evaluate these outcomes have been developed and vali-
dated. For example, an algofunctional index of severity for
OA of the knee (ISK) was developed by Lequesne et al.26
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Methods proposed for evaluating radiologic progression
of OA include semi-quantitative assessment of individ-
ual radiographic features such as marginal osteophytes,
JSN, subchondral sclerosis, and malalignment37–39.
Others suggest composite indices such as the Kellgren and
Lawrence grading40,41 and a JSN weighted scale42. Still,
other researchers applied strictly quantitative measures
employing both automated and non-automated methods of
joint space width (JSW) measurements43,44.
Physicians generally use imaging to confirm the clinical
diagnosis of OA, assessing changes in articular cartilage
either directly or indirectly. Radiological JSN is consideredthe most reliable available marker for the assessment of
OA progression in SMA clinical trials23,29,30. In support of
this, Ayral et al.45 and Blackburn et al.46,47 reported that
articular surface lesions as detected by arthroscope always
accompanied JSN on plain radiographs.
Using standardized protocols to obtain reliable radio-
graphic images of joints in the weight-bearing position is
crucial in determining articular cartilage loss in the knee
OA48–50. Reliability means the reproducibility of the quan-
titative measurement of the JSW, i.e. the degree to which
repeated measurements of JSW by the same observer, or
by different observers, produce highly correlated estimates
of JSW. Two parameters are used in the literature to
describe the reproducibility of repeated measurement of
the JSW. The first one is the coefficient of variation (CV).
CV is the ratio of the standard deviation to the mean of the
measurement. The lower the CV of a given methodology
the higher the ability to detect small changes in JSW.
Another way of assessing the reproducibility of repeated
measurements is the interclass correlation coefficient. The
higher the coefficient of a given methodology the more
reproducible it is. The latter is preferred although not
reported often in the literature.
Several factors play an important role in the reliability of
the radiologic measurement of JSW; imaging procedure,
patient positioning, and measurement method.Imaging procedure
Currently, researchers take measurements of radio-
graphic features from both standard and microfocal radio-
graphs. The difference between these two types of
radiographs is the size of the X-ray source, which is
considerably smaller for the microfocal technique51. The
advantages of the smaller source are high magnification,
high spatial resolution and minimum penumbral blurring i.e.
the radiographic margins of features are sharply defined50.
However, the small source of X-ray results in longer expo-
sure time as it limits the output of the X-ray tube. Never-
theless, patient exposure time and the level of exposure is
still within acceptable clinical parameters51. The microfocal
radiographic equipment is not widely available at present,
but the cost is similar to that of a conventional X-ray
machine, so expense is not an impediment to implementing
this superior technology52 with regard to a trial in only one
center. On the other hand, in a multi-center study the cost
will be an issue because the microfocal X-ray is not useful
for common radiographs in daily practice.Patient positioning
Lynch et al.53 and Conrozier et al.54 established that
even small changes in X-ray beam or joint position can
dramatically alter the measurement for JSW in the knee53
and hip54 joints. If clinicians do not specify their prefer-
ences when ordering films, some patients may have X-rays
taken in the lying position while others will be standing.
Moreover, X-ray technicians may have their own idiosyn-
cratic methods for positioning patients, especially those
patients with pain and difficulty in standing or walking50.
Ravaud et al.55 reported that a deviation in foot rotation
by as little as 15°, may result in significant variation in the
measurements of JSW. In addition, the position of the
center of the joint, i.e. the joint space, relative to the central
ray of the X-ray beam is crucial as it influences theand was validated over five years comparing it with other
assessment tools27. The ISK was proposed to be particu-
larly valuable in providing information on the long-term
natural disease course expected with SMA trials27. Another
tool is the Western Ontario and McMaster Universities
(WOMAC) OA index. This is a tri-dimensional, disease-
specific health status measure that probes clinically import-
ant, patient relevant symptoms in the areas of pain,
stiffness and physical function28. It is important to note that
neither the WOMAC nor the ISK allow separate evaluation
of the two knee joints. To help in determining which joint is
the symptomatic one, a visual analog scale of pain could be
used. Alternatively, the information in the pain subscale of
the WOMAC can be collected for each knee separately.
In 1996, the Task Force of OA Research Society29
published guidelines for the design and conduct of clinical
trials in patients with OA. The Task Force incorporated the
recommendations of previous committees: World Health
Organization (WHO)/International League of Associated
Rheumatologists (ILAR)30, WHO and the American
Academy of Orthopedic Surgeons31, Group of the Respect
of Ethics and Excellence in Science32 and Outcome
Measures in Rheumatoid Arthritis Clinical Trials III
(OMERACT)33. The guidelines emphasize the need for
reliable assessment tools in the research of OA, whether
measuring the clinical improvement or the progression of
OA. They reiterate that standardized protocols should be
based on published validation data.
Regardless of the tool used to document clinical
improvement, an important question has emerged; can
clinical improvement in OA patients be used as a surrogate
for structure modification? In the general population, self-
reported symptoms are associated with the severity of
radiographic changes of OA3,16,34. However, this finding
has not been reported in diagnosed OA patients, especially
with regard to joint space narrowing (JSN)22,35,36. In a
long-term follow up study of 400 OA patients by Dieppe
et al.22, there was no correlation between radiographic and
clinical changes. Nevertheless, it is important to emphasize
that available clinical and radiological evaluative method-
ologies of OA are not optimal. This may explain some of the
discrepancy between clinical and radiological findings
among various studies. In this context, lack of the ability to
detect early signs of the disease process represents one of
the challenges. Other potential issues of importance are
the confounding effect of the use of pain medication by
patients, dropout of patients due to joint replacement and
the differences in the characteristics of the study popu-
lations among various studies. Further research is needed
to elucidate the relationship between clinical improvement
and structural changes among OA patients.
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decrease in JSW was observed when the X-ray beam was
displaced by 1 cm below its original alignment centered at
the mid-point of the patella. The positioning of the center of
the joint can be influenced by factors such as obesity and
restriction of joint movement. Buckland-Wright et al.49
affixed a magnification marker (a 5-mm ball encased in
plexiglass) with tape to the skin overlying the head of the
fibula to correct for the degree of magnification. This was
after the investigators reported a variation in magnification
of the JSW ranging from 9 to 35%. Thus, it is not surprising
that in SMA trials, failure to correct for this variability
has significant negative implications on the study power
therefore necessitating larger sample sizes.29
Another pertinent aspect of positioning is the degree to
which the knees are flexed. Ravaud et al.55 reported that
up to a 12.5% variation in tibio-femoral JSW measurements
occurred when they repeatedly radiographed normal knees
manipulating knee flexion by as little as 5°. The guidelines
published by the Task Force of OA Research Society
International29 described two different protocols for radi-
ography of the knee OA. In one, the patient stands with the
knees fully extended44,55,56 while in the other, the patient
stands with the knees semi-flexed43,49,53,57,58. The fully
extended position is fraught with errors because cartilage
loss is not even throughout the joint. Frequently articular
cartilage is spared at the anterior margin of the tibia even
when there has been considerable loss from the central
articular region in the tibial plateau at the point of weight
transmission. Consequently, joint space measurements in
the medial compartment of such knees provide an inaccu-
rate measurement of the extent of cartilage preservation,
usually overestimated50.
In the standing semi-flexed view each knee is radio-
graphed separately to overcome the differences in the
required degree of flexion between the left and the right
knees. Each knee is flexed until the medial compartment of
the tibial plateau is horizontal relative to the floor of the
room and parallel to the central ray of the X-ray beam. In
this position, the femoral condyle occupies a postero-
central position on the articular surface of the tibia. This
position coincides with the site of principle load across the
joint during its normal function50. Messieh et al.59 con-
firmed that this is the site at which arthroscopy has
revealed the highest prevalence of articular cartilage
destruction. Therefore, it is not surprising that the standard
deviation of JSW measurements taken on knees filmed
using the standing extended view was found to be
2.0 mm,60 while Buckland-Wright et al.53, using computer-
ized measurements of JSW and the semi-flexed view,
reported standard deviations between 0.5 and 0.79 mm.Measurement method
Examiners can obtain measurements of JSW either
manually or using a computer. Lequesne61 described a
standardized method of manual measurement of JSW
(chondrometry). Several specialized edge-detection com-
puter software applications have been developed to
measure JSW in digitized radiographic images53,62–64.
Mazzuca et al.65 concluded that the poor reproducibility of
measurements of JSW, the slow rate of OA progression,
and the practicalities and cost of clinical trials precluded the
use of the conventional radiographic technique using
manual measurements of JSW in SMAs trials. The authors
clearly showed that the use of computerized measurementof JSW using films taken in the semi-flexed position is
expected to reduce the required sample size by 44%. This
smaller sample size will allow reductions in patient
recruitment, screening and post-randomization costs.
Buckland-Wright et al.49 used a specially prepared
computer program for tibio-femoral joint space analysis,
measuring the interbone distance at 300 points across the
compartment and selecting the narrowest point, the mini-
mum JSW. Using a standard radiograph of the knee in the
semi-flexed position, they reported coefficients of variation
(CV) for repeated measurement as low as 1% for the
medial and 1.5% for the lateral compartments.
Another method that was proposed is the mean JSW.
Although the minimum JSW could be more sensitive to pick
changes in cartilage than the mean JSW, the latter is less
susceptible to the influence of the variation in both radio-
graphic procedures and patient positioning and remains
possible when the interbone distance is very small66.
Therefore, some authors suggested the measurement of
both parameters, minimum JSW and mean JSW in SMAs
trials67.Commentary
In summary, Buckland-Wright et al.49 and Buckland-
Wright50 clearly show that the precision and accuracy of
JSW measurements are best maximized by fulfilling sev-
eral parameters; (1) measuring the minimum JSW in the
tibio-femoral medial compartment, (2) using computerized
measurements, (3) correcting for radiographic magnifica-
tion, (4) obtaining standard radiograph of the knee in the
standing semi-flexed view, and (5) using microfocal
radiography.
Unfortunately, the precision associated with the level of
standardization used in Buckland-Wright’s technique
comes with certain costs represented in the need for
special training of investigators in radio-anatomic position-
ing, use of fluoroscopy and image digitization with special-
ized computer software and hardware. In addition, the
technique is highly technician dependent even after train-
ing. According to Mazzuca et al.65, high inter-investigator
reproducibility of radio-anatomic positioning of the knee still
needs to be established. Furthermore, microfocal radiogra-
phy of joints is not widely available in clinical radiology
departments in the US and consequently this technique
could not be easily employed in a multi-center study65.
Perhaps pressured with the logistical limitations of the
fluoroscopic-based technique, Buckland-Wright et al.68
conducted a comparative study of three non-fluoroscopic
radiographic views: standing extended, semi-flexed, and
schuss. The study showed that, radioanatomically, knees in
the semi-flexed view were significantly more accurately
positioned than in the schuss view, which in turn was better
than the extended knee view. Furthermore, joint reposition-
ing and reproducibility of JSW were significantly better in
the semi-flexed view than in the other two views.
In this context, it is important to note that there are other
limitations of the radiographic assessment of JSW in gen-
eral. First, radiographs cast a two-dimensional image of a
three-dimensional structure on a flat receptor. This allows
large portions of the anatomy to be depicted as a single
image. This is associated with a superimposition of over-
lapping structures potentially obscuring structural abnor-
malities. Second, it is difficult to compare the size of joint
spaces between patients especially when the actual
radiologic magnification is unknown. For this reason,
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percentage of change relative to each patient’s baseline
films64. Finally, even with the best techniques, radiographs
were found to underestimate the extent of cartilage
damage when compared to arthroscopy46,69.MAGNETIC RESONANCE IMAGING
MRI has the potential to provide high quality images of
soft tissue allowing visualization of the anatomy and its
pathology. MRI is unique in being able to directly visualize
all components of the joint simultaneously. This capability
allows the examiner to study the entire organ, and places
OA in the accurate context of a disease of organ failure70.
Buckland-Wright50 published a review of the differences
among radiography, arthroscopy and MRI. He concluded
that MRI is more sensitive than radiography for detecting
OA joint characteristics and is unique in assessing soft
tissue changes. In particular, the fat-suppressed three-
dimensional spoiled gradient-echo (SPGR) MRI was found
to be faster and significantly more sensitive than the
standard MRI technique in detecting hyaline cartilage
defects70–72. The SPGR further achieved excellent repro-
ducibility among readings and between readers71,73. This
technique is widely available and easy to perform using any
high-field MRI scanner in clinical use.
On the other hand, some studies report moderate corre-
lation between MRI and arthroscopy in detecting certain
cartilage lesions. Early grade 1 subchondral sclerosis74
and early changes, particularly in articular cartilage75, were
difficult to detect using MRI. Others suggested that an MRI
scoring system is still required and the ability of an MRI to
precisely measure changes in cartilage thickness over time
in a large joint, such as the knee, has not been sufficiently
validated25,65,76–78. The total volume of cartilage readily
assessed by the MRI offers limited information about the
distribution of cartilage changes in the OA joint and conse-
quently is insensitive to focal changes. In addition, its use is
difficult in multi-center trials because of the high cost of the
MRI machines and the need for highly skilled and specially
trained readers.ARTHROSCOPY
Arthroscopy permits direct magnified visualization of the
articular cartilage and is thus very sensitive in detecting
surface cartilage defects. Chondroscopy is a simplified
technique of arthroscopy. The procedure can be performed
with a small arthroscope, under local anesthesia, in an
outpatient setting45. According to Ike and O’Rourke79,
using this technique enables investigators to assess as
much as 90% of the articular surface. A scoring and grading
system proposed by the committee of the French Society of
Arthroscopy80 has been found to have high reliability and
low interobserver variation81. Unfortunately, arthroscopy
does not allow the assessment of softening and thickening
of cartilage or changes in the juxtaarticular tissues. Further-
more, the procedure is invasive, subjecting the patient to a
variety of risks, and unlikely to be used for frequent
follow-up assessment. However, it may have a role in
establishing comparative criteria for MRI or other imaging
techniques.ULTRASOUND
Ultrasound is an appealing approach because of its ease
of performance and low cost. Its ability as a method ofdetecting cartilage damage was first studied by Aisen et
al.82 who were able to show significant reduction in carti-
lage thickness in patients with knee OA compared to
normal subjects. Ultrasound was further studied by Myers
et al.83 reporting high accuracy and reproducibility of
measurements of the thickness and surface characteristics
of normal and OA articular cartilage. Several authors have
suggested the use of ultrasound as an evaluative method
for cartilage lesion progression during and after OA
therapy84,85. Pipitone et al.86 used ultrasound to document
that knee OA patients treated with chondroitin-sulfate main-
tained articular cartilage as compared to the control group.
However, ultrasound relies on the examiner moving the
transducer in a steady manner. Orienting the images prop-
erly requires knowing the exact positioning of the trans-
ducer relative to a given anatomy. In addition, many areas
remain inaccessible because of the overlying bone. These
factors render ultrasound highly examiner-dependent and
time consuming. The sensitivity of this technique in
documenting pathologic changes in OA requires further
evaluation77.BIOLOGIC MARKERS
Biologic markers reflect the ongoing dynamic metabolic
processes in joint tissues such as cartilage, synovium and
bone. Because the ability to sample and monitor these
tissues is limited, synovial fluid, blood and urine are cur-
rently the only windows to the pathologic processes taking
place in the joint. Cartilage oligomeric matrix protein
(COMP)87 and collagen II C-propeptide88 are examples of
markers detected in synovial fluid. Other candidate
markers for OA may be found in one or more body fluids.
Hyaluronate19 epitopes shown to reflect de-novo proteogly-
can synthesis (e.g. 846, 3B3)89,90, C-reactive protein91,
CYLK 40 (chondrex)92 and metalloproteinases and their
tissue inhibitors93 are examples of other biologic markers.
For specific details about individual markers
readers can refer to any of several published review
articles94,97.
There are several applications for biologic markers sug-
gested by researchers. Some of these applications include
being used as a diagnostic test for OA98; as an evaluative
test for severity or staging of OA99,100; as a prognostic test
to identify patients more likely to show rapid progression of
OA19–21,91 and as a surrogate outcome measure in clinical
trials of SMAs. Unfortunately, the goal of using these
markers in assessing the disease process of OA during
clinical trials has not been reached76,96. To date, the use of
biologic markers in this application is limited to rheumatoid
arthritis101. Several authors suggest that in order to
remedy this, researchers should collect samples of body
fluids in future OA clinical trials to help validate various
markers96,97.
Notwithstanding the wide array of suggested benefits,
the role of biologic markers in OA is still under investigation
and there exist several challenges to determining their
usefulness96,97.
(1) The concentration of markers in these fluids may
depend not only on the dynamics of the disease
process but also on such factors as the rate of
elimination or clearance from the sampled body
compartments and the amount of cartilage
remaining in the joint102,103. For example, even
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clearance104.
(2) Treatment with non-steroidal antiinflammatory drugs
and corticosteroids might decrease the volume of joint
effusion, increasing marker concentration or inhibiting
the production of some markers105,106.
(3) The specific source of the marker is difficult to discern
both on the level of the tissue107 and the level of the
metabolic process. This issue is even more pertinent
when serum or urine samples are assayed. One
problem is that not all markers are studied for their
relative specificity for both degradative and synthetic
events96. An increase in the level of a specific carti-
lage matrix marker could reflect either an increase in
degradation or an increase in new synthesis. Another
problem occurs when a given fragment of matrix
molecule, proposed to be used as a marker, is not
present in more abundance in cartilage than in any
other joint tissue. For example, the total mass of
COMP in the menisci of a knee may approach that in
the joint cartilage of the knee108.
(4) Changes in lymphatic and hepatic function will affect
the clearance of cartilage markers from serum as
these organs are responsible for elimination96.
(5) There is considerable overlap between OA patients
and those in control groups. Possibly this is because
serum and/or synovial fluid concentrations of some
markers are influenced by age and gender109, by
change in physical activity110,111, or simply by cir-
cadian variations112.
(6) Methodological limitations of the available data can
interfere with the interpretation of findings, e.g. data
collected from cross-sectional studies96. The manner
in which patients are grouped reportedly significantly
affected measurements113. Hence, careful patient
characterization is needed to increase the value of
markers96.
Another important methodological challenge is assay
methods. Assay sensitivity varies according to whether the
antibody used is monoclonal or polyclonal, and variations
exist between one kit and another114.
For these reasons, identification of a single biological
marker seems to be an unrealistic goal97. Using a combi-
nation of several markers might eventually provide better
information on the various stages of the pathological pro-
cess of OA. Further research is still warranted before this
approach proves beneficial in the context of SMA trials.Patient selection in SMA trials of knee OA
HOMOGENEOUS POPULATIONS
The variance of JSN has two components: measurement
error in the assessment of JSW and biologic variation in
rate of OA progression. Measurement error is expected to
decrease the correlation among repeated measurements
of JSW consequently reducing the study power115. Reduc-
ing measurement error can be attained by selecting
appropriate standardized method of measuring JSN as
discussed earlier. Reducing the biologic variation can be
achieved by studying a ‘homogeneous’ patient population.
Inevitably, this might limit the generalizability of the results,
but the practical limitations in current imaging and analyti-
cal methods make other choices unrealistic. Therefore, it is
not surprising that many authors advocate the use of
homogeneous populations of patients25,116.SOURCE OF PATIENTS’ RECRUITMENT
A possible source of biologic variation stems from the
fact that the progression among patients in the general
elderly population suffering from OA, who are likely to be
identified by community-based recruitment, may be slower
than that in a clinic-based population of patients65. Among
a group of 252 knee OA patients referred to a hospital,
Ledingham et al. found that the majority had bilateral OA
affecting more than one compartment of the knee117,
suggesting a more advanced disease state. Therefore, it
was suggested to stratify participants by recruitment source
during their randomization to treatment groups. This may
assist with balancing the potential differences in the rate of
JSN65.LENGTH OF FOLLOW UP
Because of problems such as a high rate of dropping out,
it is preferred to follow large numbers of patients for shorter
periods rather than fewer patients for longer periods118,119.
On the other hand, for the vast majority of patients, the
mean joint space will diminish with time120,121. Thus, the
longer the period of observation, the smaller the variability
of JSN in relation to the mean65, which increases the study
power. A fine balance should be attempted for this trade-off
between the number of patients and the length of follow-up.
Some investigators have suggested a 2-year follow-up
period for these studies to be able to demonstrate radio-
logically significant improvement in OA50,65. Unfortunately,
the optimal follow-up duration in SMAs trials has not been
agreed upon; therefore, clinical trials should establish
this duration based on both previous data and the
characteristics of the studied populations122.RATE OF OA PROGRESSION
While the rate of OA progression is variable over time in
the same patient and between patients96, estimates of the
rate of medial tibio-femoral JSN among knee OA patients
do exist in the public domain16,49,56,60,61,123. The estimated
annual rate of JSN ranged from 0.06 mm/year16 to
0.60 mm/year56,60. The likely reason for this 10-fold vari-
ation are the differences between the studies in both
patient characteristics and methodological features65. This
finding supports the notion of using a homogeneous
population of patients as noted earlier.
Currently, there is little known about the factors control-
ling progression of OA50. Knowledge of these factors would
have a huge impact on the design of SMA trials, tremen-
dously increasing the study power. Several studies have
suggested criteria for selecting patients more likely to show
rapid progression including biological markers in the
serum19,91, imaging procedures such as scintigraphy18 and
epidemiological findings12,14,124. These studies will be
addressed briefly in the following section.Biological markers
Sharif et al.19 studied the prognostic value of serum
hyaluronic acid (HA) levels in relation to OA of the knee.
They followed 94 patients for 5 years. Patients whose OA
had progressed were found to have had significantly higher
levels of serum HA at baseline, compared with those whose
OA had not progressed.
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level increase in serum C-reactive protein (CRP) and the
progression of OA. They studied 105 knee OA patients for
4 years and found levels of CRP significantly higher in
those that progressed radiographically than in other
patients. CPR production is stimulated by cytokines, par-
ticularly interleukin-6, and the investigators interpreted their
results as unequivocal evidence of a chronic low-level
activation of the cytosine cascade reflecting tissue-
damaging process within the joints. However, it is prema-
ture to advocate using such markers to choose target
patient populations. Further research is warranted to verify
the findings of these studies. Other methodological
challenges faced when using biologic markers were
discussed above in a previous section.Bone scintigraphy
A number of groups have used scintigraphy to study the
relationship between isotope (technetium-labeled diphos-
phonate, 99 mTc) retention and radiologic indices of OA
severity18,20,125–127. They showed a significant correlation
between scintigraphic bone scan abnormalities and bio-
logic markers of bone turnover in synovial fluids20 and
suggested that scintigraphy may serve as a predictor of
subsequent progression in OA126. Dieppe et al.18 verified
this notion by reporting that 88% of the knees with severe
scan abnormalities at baseline showed JSN, whereas none
of the knees without scan abnormalities showed JSN by the
end of 5 years. These findings might be perceived as
valuable in the design of SMA trials in that a negative scan
informs investigators that OA is unlikely to progress over
the next few years and that a particular patient is not an
ideal candidate for a particular SMA trial. However, the
main drawback is the impracticality of implementing this
approach. Scintigraphic bone scan is not done routinely for
OA patients and is prone to pose a logistical challenge for
recruitment of ‘eligible’ patients.Epidemiological studies
There have been several epidemiological studies con-
ducted to ascertain predictive factors for the progression of
OA12,14,124. For example, data from Chingford, U.K., sug-
gest that 50% of obese, middle-aged women with radio-
graphic evidence of unilateral knee OA may develop OA in
the contra-lateral knee within two years14. Therefore, this
group is considered at high risk for rapid progression of OA,
making them desirable for SMA trials. Other risk factors
for OA progression include advanced age especially
among women128, coexistence of crystalline diseases, con-
current OA in multiple joints and neuropathy117,129. Patrick
et al.124 reported association between calcium pyrophos-
phate dihydrate (CPPD) in synovial fluid and higher mean
scores for arthritic changes including joint space loss.
Another study reported that JSN was associated with
worsening symptoms and function, clinical inflammation
(effusion and warmth) and the presence of CPPD in syno-
vial fluid12. To avoid hampering the efforts of recruitment of
patients, it would be advisable to try to satisfy as many of
these risk factors as possible rather than restricting the
study population to fulfill a specific risk factor.CONCOMITANT THERAPY
It is worthwhile noting that the use of rescue medication
would influence the drop out rate in clinical trials of SMAs.In two long-term studies, only 57% and 35% of the random-
ized study subjects completed the 2 years’ duration of
these studies118,119. These findings favor providing symp-
tomatic ‘rescue treatment’ as part of the study protocol as it
appears that most of the withdrawals in these studies were
due to a lack or delay of symptomatic relief. It is important
to emphasize that studies of putative SMAs might be
ethically compared to placebo if supplemental acetami-
nophen or NSAIDs are allowed to control symptomatic
exacerbation(s)30,79, because at this time no agent can be
taken as a benchmark for the treatment of OA. However, in
considering rescue medications, special attention should
be given to indomethacin because of its potential detrimen-
tal effect on cartilage.TARGET COMPARTMENT OF THE KNEE JOINT
The knee joint is a complex articulation that can be
regarded as having two functionally distinct compartments,
the tibio-femoral (TF) which is further separated into the
medial and lateral aspects; and the patello-femoral (PF)
compartment. Determination of which compartment is
affected in OA can be difficult and is highly dependent on
the radiographic view130. Pathologic studies indicate that
OA in the knee joint is heterogeneous in terms of its sites of
involvement and that these sites may be affected indepen-
dently131,132. The extent to which this may occur radio-
graphically has been illustrated in clinical series117 and in a
community survey133. These studies found the most com-
mon patterns of localization of OA within the knee to be
medial TF (45%), followed by PF (35%), and demonstrated
that each of these is independently associated with sub-
stantial pain and disability. Furthermore, the relative contri-
bution of mechanical and constitutional factors in the
pathogenesis of OA in different compartments of the knee
joint might vary134. Even clinically, a questionnaire like the
ISK was validated only for TF OA because OA in the PF
compartment is too irregular in pain and severity and it is
not a good ‘model’ for trials26. Therefore, it has been
suggested that clinical trials should not include a mix of
patients with TF and PF knee OA, rather they should be
treated as separate disorders25.
In a study by Buckland-Wright et al.135, the JSW in the
lateral TF compartment remained similar to that of non-
arthritic joints. This might account for the radiographically
observed lower frequency and severity of cartilage loss in
the lateral TF compartment. Moreover, in the Chingford
study, the intra- and interobserver reproducibility of the
radiographic quantitative measurement of the medial TF
compartment was found to be much better than the lateral
TF compartment136. In another study, Wada et al.137 found
that the positive predictive value of JSN in the medial TF
compartment of the knee for the presence of abnormal
articular cartilage by the arthroscopy was high (98%), while
it was poor in the lateral TF compartment (20%).
Equally important is the choice of the target knee when
the OA is bilateral. Clinically, many investigators would ask
the patient to identify the most symptomatic knee and label
it as the ‘study knee’138. However, the radiographic picture
is not as straightforward. The dilemma stems from the pool
of significant association between the clinical and the
radiographic changes in OA as noted earlier. The current
recommendation is to measure the JSN bilaterally even if
the contralateral involvement is asymptomatic30.
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A SMA is expected to demonstrate more efficacy in OA
joints that have mild to moderate pathology than in joints
with severe disease45,114. In experimental animals, when
treatment began before histologic changes in cartilage
started, the severity of OA was remarkably reduced139–141.
On the other hand, JSN accelerates with OA severity65,
which increases the study power as discussed earlier.
Therefore, a fine balance should be sought between
recruiting patients with mild enough OA to show efficacy of
the studied SMA, and at the same time are severe enough
to guarantee a reasonable rate of OA progression. Such
formula might be found among patients with several years’
duration of OA, rather than in newly diagnosed patients.
Clinically, pain is considered to be the most important
symptom and consequently the most important outcome
measurement, but it is not yet clear what minimal frequency
and severity of pain should be required for entry to SMAs
trials25,116. Perhaps a minimal clinical level, similar to that
which is well justified for symptomatic studies to provide a
‘room’ for improvement, may not be necessary for SMAs
trials because the main outcome is more likely to be based
on radiographic improvement.Sample size calculations and study power
Buckland-Wright50 published criteria for selecting the
study OA knee as follows: (1) the knee must have medial
tibio-femoral compartment JSW more than 2 mm; (2)
osteophytosis and subchondral sclerosis should be visible;
and (3) the joint must have had pain for at least 15 days in
one month. The author further suggested that for 2 years’
duration, comparing active agent against placebo, the total
number of OA knees required to detect a significant differ-
ence in minimum JSW using microfocal radiography is 166,
222, and 274 for study power of 80%, 90% and 95%,
respectively. The working assumptions are equal patient
groups, a mean annual rate of JSN of 0.183 mm/year with
a standard deviation of 0.196 mm49, a protective effect of
the therapeutic agent of 30%, and implementation of com-
puterized measurement of the JSW. The same calculation
for standard plain radiographs yielded longer duration and
considerably more patients. In another study, Mazzuca
et al.65 estimated that in a 2-year SMA study, 87 patients
per group would be necessary to detect a significant
difference in JSN between treatment and placebo groups.
This group’s ‘working assumptions’ were JSN at a rate of
0.25 mm/year, a treatment effect of 30% and a study power
of 80%.
These estimates present the number of patients that will
‘complete’ a given SMA trial. It is important to consider the
expected high drop out rate in the calculation of the optimal
sample size. The accuracy of this type of trial can be further
enhanced by radiographic follow-up of all patients even if
they dropped out of the study. This will enable the applica-
tion of the intention-to-treat analysis, in which patients’ data
are considered in their original group of randomization
regardless of compliance. Another important issue to con-
sider is that the adjustment for potential confounding
attributes may increase the study power. Therefore,
the collection of such data as age, gender, body mass
index, physical activity, occupation, and smoking are
recommended77.
Finally, it is important to emphasize, as discussed earlier,
that the actual sample size calculations will be very sensi-tive to many study-specific parameters, including charac-
teristics of the target study population, sampling technique,
imaging method, outcome parameters and expected effect
size. This situation might require performing a pilot study
before the initiation of any large-scale long-term SMA study
and not just relying upon published data.
In conclusion, it is obvious that SMAs have the potential
to provide another valuable tool in the armamentarium
against OA. However, scientists are faced with several
challenges when attempting to document OA progression
using available techniques of imaging. Further studies are
still required to evaluate and compare the reproducibility
and sensitivity of various techniques purported to assess
changes in OA disease process.References
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